Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press171310.17650/1726-9776-2023-19-4-61-76DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железыMultiparametric magnetic resonance imaging in diagnosis of local prostate cancer recurrence after radiation therapy and radical prostatectomy: a unified PI-RR reporting systemМультипараметрическая магнитно-резонансная томография в диагностике локального рецидива рака предстательной железы после лучевой терапии и радикальной простатэктомии: унифицированная система отчета PI-RRhttps://orcid.org/0000-0001-8378-4338RubtsovaN. A.РубцоваН. А.
Russian Federation

3 2nd Botkinskiy Proezd, Moscow 125284

Рубцова Наталья Алефтиновна

125284 Москва, 2-й Боткинский пр-д, 3

rna17@yandex.ruhttps://orcid.org/0000-0002-3398-4128AlekseevB. Ya.АлексеевБ. Я.
Russian Federation

3 2nd Botkinskiy Proezd, Moscow 125284,

11 Volokolamskoe Shosse, Moscow 125080

Алексеев Борис Яковлевич

125284 Москва, 2-й Боткинский пр-д, 3,

125080 Москва, Волоколамское шоссе, 11

byalekseev@mail.ruhttps://orcid.org/0000-0001-8784-8415KaprinA. D.КапринА. Д.
Russian Federation

3 2nd Botkinskiy Proezd, Moscow 125284,

6 Miklukho-Maklaya St., Moscow 117198

Каприн Андрей Дмитриевич

125284 Москва, 2-й Боткинский пр-д, 3,

117198 Москва, ул. Миклухо-Маклая, 6

kaprin@mail.ruhttps://orcid.org/0000-0001-6483-2074KryuchkovaO. V.КрючковаО. В.
Russian Federation

15 Marshala Timoshenko St., Moscow 121359

Крючкова Оксана Валентиновна

121359 Москва, ул. Маршала Тимошенко, 15

ovk16@bk.ruhttps://orcid.org/0000-0002-3521-8937TalyshinskiiA. E.ТалышинскийА. Э.
Russian Federation

Ali E. Talyshinskii 

7–9 Universitetskaya Naberezhnaya, Saint Petersburg 199034, 

49a Beybitshilik St., Astana 010000, Kazakhstan

Талышинский Али Эльманович

199034 Санкт-Петербург, Университетская набережная, 7–9,

Республика Казахстан, 010000 Астана, ул. Бейбитшилик, 49а

ali-ma@mail.ruP.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of RussiaМосковский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииMedical Institute of Continuing Education, Russian Biotechnological UniversityМедицинский институт непрерывного образования ФГБОУ ВО «Российский биотехнологический университет»Medical Institute, Peoples’ Friendship University of Russia named after Patrice LumumbaМедицинский институт ФГАОУ ВО «Российский университет дружбы народов им. Патриса Лумумбы»Central Clinical Hospital with a Polyclinic of the Administration of the President of the Russian FederationФГБУ «Центральная клиническая больница с поликлиникой» Управления делами Президента Российской ФедерацииSaint Petersburg State UniversityФГБОУ ВО «Санкт-Петербургский государственный университет»Astana Medical UniversityНАО «Медицинский университет Астана»29122023194617616082023011020232023https://oncourology.abvpress.ru/oncur/article/view/1713

Multiparametric magnetic resonance imaging (mpMRI) has an indisputable advantage in diagnosis of local recurrences of prostate cancer (PCa). Even though mpMRI has been shown to be very informative for detection of local PCa recurrences, high variability in its application and interpretation remains. Experts from the European Society for Urogenital Radiology (ESUR), the Imaging Committee of the European Association of Urology (ESUI), and several members of the PI-RADS committee developed a unified report system called Prostate Imaging Recurrence Reporting (PI-RR) to measure the risk of local recurrence of PCa in men who have had radical prostatectomy and radiation therapy and are being followed up. The principles of mpMRI that form the basis of PI-RR are well known and are stated in the PI-RADS v.2.1 guidelines, which have proven their diagnostic efficiency. The PI-RR system has the potential to become an important tool for improving communication between specialists involved in the process of PCa diagnosis and treatment, for optimizing treatment strategy in patients with local PCa recurrence, and for improving survival rates in patients with PCa after specialized anticancer treatment.

Для диагностики локального рецидива рака предстательной железы (РПЖ) неоспоримым преимуществом обладает мультипараметрическая магнитно-резонансная томография (мпМРТ). Несмотря на доказанно высокую информативность мпМРТ в выявлении локальных рецидивов РПЖ, до настоящего времени отмечается существенная вариабельность в подходах к ее проведению и интерпретации. Экспертами Европейского общества урогенитальной радиологии (ESUR), комитета по визуализации Европейской ассоциации урологов (ESUI) и отдельными членами комитета PI-RADS была разработана система унифицированного отчета для оценки риска локального рецидива РПЖ у пациентов после радикальной простатэктомии и лучевой терапии в процессе динамического наблюдения – prostate imaging recurrence reporting (PI-RR). Принципы проведения мпМРТ, заложенные в основу PI-RR, хорошо известны и отражены в рекомендациях PI-RADS v.2.1, доказавших свою диагностическую эффективность. Система PI-RR может стать важным инструментом для улучшения коммуникации между специалистами, участвующими в процессе диагностики и лечения РПЖ, оптимизируя лечебную стратегию у пациентов с локальным рецидивом РПЖ, повышая показатели выживаемости пациентов после специализированного противоопухолевого лечения.

prostate cancerrecurrencemultiparametric magnetic resonance imagingPI-RRрак предстательной железырецидивмультипараметрическая магнитно-резонансная томографияPI-RRSomov A.N., Suslin S.A. Prostate cancer. Epidemiology, risk factors and early detection. Profilakticheskaya meditsina = Russian Journal of Preventive Medicine 2020;23(3):149–55. (In Russ.). DOI: 10.17116/profmed202023031149Сомов А.Н., Суслин С.А. Рак предстательной железы. Эпидемиология, факторы риска и раннее выявление. Профилактическая медицина 2020;23(3):149–55. DOI: 10.17116/profmed202023031149Nosov D.A., Volkova M.I., Gladkov O.A. et al. Practical guidelines on treatment of prostate cancer. Zlokachestvennie opukholi: Prakticheskie Rekomendatsii RUSSCO = Malignant Tumors: RUSSCO Practical Guidelines 2022;12(3s2):607–26. (In Russ.). DOI: 10.18027/2224-5057-2022-12-3s2-607-626.Носов Д.А., Волкова М.И., Гладков О.А. и др. Практические рекомендации по лечению рака предстательной железы. Злокачественные опухоли: Практические рекомендации RUSSCO 2022;12(3s2):607–26. DOI: 10.18027/2224-5057-2022-12-3s2-607-626Kim M., Hwang S., Ahn H. et al. Diagnostic yield of multiparametric MRI for local recurrence at biochemical recurrence after radical prostatectomy. Prostate Int 2022;10(3):135–41. DOI: 10.1016/j.prnil.2022.05.001Petrovsky N.V., Glybochko P.V., Alyaev Yu.G. Local recurrence of prostate cancer after radical prostatectomy. Urology 2017;(4):85–90. (In Russ.). DOI: 10.18565/urol.2017.4.85-90Петровский Н.В., Глыбочко П.В., Аляев Ю.Г. и др. Локальный рецидив рака предстательной железы после радикальной простатэктомии. Урология 2017;(4):85–90. DOI: 10.18565/urol.2017.4.85-90De Visschere P.J.L., Standaert C., Fütterer J.J. et al. A systematic review on the role of imaging in early recurrent prostate cancer. Eur Urol Oncol 2019;2(1):47–76. DOI: 10.1016/j.euo.2018.09.010Kaprin A.D., Alekseev B.Ya., Matveev V.B. et al. Prostate cancer. Clinical recommendations. Sovremennaya onkologiya = Journal of Modern Oncology 2021;23(2):211–47. (In Russ.). DOI: 10.26442/18151434.2021.2.200959Каприн А.Д., Алексеев Б.Я., Матвеев В.Б. и др. Рак предстательной железы. Клинические рекомендации. Современная онкология 2021;23(2):211–47. DOI: 10.26442/18151434.2021.2.200959Teeter A.E., Griffin K., Howard L.E. et al. Does early prostate specific antigen doubling time after radical prostatectomy, calculated prior to prostate specific antigen recurrence, correlate with prostate cancer outcomes? A report from the SEARCH Database Group. J Urol 2018;199(3):713–8. DOI: 10.1016/j.juro.2017.08.107Cornford P., van den Bergh R.C.N., Briers E. et al. EAU-EANMESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol 2021;79(2):263–82. DOI: 10.1016/j.eururo.2020.09.046Tokas T., Grabski B., Paul U. et al. A 12-year follow-up of ANNA/ C-TRUS image-targeted biopsies in patients suspicious for prostate cancer. World J Urol 2018;36(5):699–704. DOI: 10.1007/s00345-017-2160-zAlekseev B.Ya., Nyushko K.M., Krasheninnikov A.A. et al. Methods for the diagnosis and treatment of oligometastases in patients with prostate cancer and progressive disease after radical treatment. Onkourologiya = Cancer Urology 2016;12(2):64–73. (In Russ.). DOI: 10.17650/1726-9776-2016-12-2-64-73Алексеев Б.Я., Нюшко К.М., Крашенинников А.А. и др. Методы диагностики и лечения олигометастазов у больных раком предстательной железы с прогрессированием заболевания после проведенного радикального лечения. Онкоурология 2016;12(2):64–73. DOI: 10.17650/1726-9776-2016-12-2-64-73EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94 92671-19-6.Chade D.C., Eastham J., Graefen M. et al. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol 2012;61(5):961–71. DOI: 10.1016/j.eururo.2012.01.022Magnetta M.J., Casalino D., Heller M.T. Imaging assessment of local recurrence of prostate cancer after radical prostatectomy. Abdom Radiol 2020;45(12):4073–83. DOI: 10.1007/s00261-020-02505-7Panebianco V., Villeirs G., Weinreb J.C. et al. Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus-based Guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy. Eur Urol Oncol 2021;4(6):868–76. DOI: 10.1186/s13014-016-0671-1Allen S.D., Thompson A., Sohaib S.A. The normal post-surgical anatomy of the male pelvis following radical prostatectomy as assessed by magnetic resonance imaging. Eur Radiol 2008;18(6):1281–91. DOI: 10.1007/s00330-008-0867-3Mertan F.V., Greer M.D., Borofsky S. et al. Multiparametric magnetic resonance imaging of recurrent prostate cancer. Top Magn Reson Imaging 2016;25(3):139–47. DOI: 10.1097/RMR.0000000000000088Patel P., Mathew M.S., Trilisky I., Oto A. Multiparametric MR imaging of the prostate after treatment of prostate cancer. Radiographics 2018;38(2):437–49. DOI: 10.1148/rg.2018170147Kowa J.Y., Soneji N., Sohaib S.A. et al. Detection and staging of radio-recurrent prostate cancer using multiparametric MRI. Br J Radiol 2021;94(1120):20201423. DOI: 10.1259/bjr.20201423Gaur S., Turkbey B. Prostate MR imaging for posttreatment evaluation and recurrence. Urol Clin North Am 2018;45(3):467–79. DOI: 10.1016/j.ucl.2018.03.011Rubtsova N.A., Mishchenko A.V., Danilov V.V. et al. PI-RADS v2.1: moving towards clarity (comments on the updated version). Onkourologiya = Cancer Urology 2020;16(2):15–28. (In Russ.). DOI: 10.17650/1726-9776-2020-16-2-15-28Рубцова Н.А., Мищенко А.В., Данилов В.В. и др. PI-RADS v2.1: движение на пути к ясности (комментарии к обновленной версии). Онкоурология 2020;16(2):15–28. DOI: 10.17650/1726-9776-2020-16-2-15-28Kaprin A.D., Biryukov V.A., Chernichenko A.V. et al. Prostate cancer brachytherapy. Experience of the branches of the National Medical Research Center of Radiology. Onkourologiya = Cancer Urology 2018;14(1):94–9. (In Russ.). DOI: 10.17650/1726-9776-2018-14-1-94-99Каприн А.Д., Бирюков В.А., Черниченко А.В. и др. Брахитерапия рака предстательной железы. Опыт работы филиалов Национального медицинского исследовательского центра радиологии. Онкоурология 2018;14(1):94–9. DOI: 10.17650/1726-9776-2018-14-1-94-99Maurer T., Eiber M., Fanti S. et al. Imaging for prostate cancer recurrence. Eur Urol Focus 2016;2(2):139–50. DOI: 10.1016/j.euf.2016.02.006Van der Poel H., Grivas N., van Leeuwen P. et al. The role of MRI for detection and staging of radio- and focal therapy-recurrent prostate cancer. World J Urol 2019;37(8):1485–90. DOI: 10.1007/s00345-019-02677-yPatel P., Oto A. Magnetic resonance imaging of the prostate, including pre- and postinterventions. Semin Intervent Radiol 2016;33(3):186–95. DOI: 10.1055/s-0036-1586144Maenhout M., Van Vulpen M., Moerland M. et al. Second salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer. J Contemp Brachytherapy 2017;9(2):161–6. DOI: 10.5114/jcb.2017.67015McCammack K.C., Raman S.S., Margolis D.J.A. Imaging of local recurrence in prostate cancer. Future Oncol 2016;12(21):2401–15. DOI: 10.2217/fon-2016-0122Pucar D., Shukla-Dave A., Hricak H. et al. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 2005;236(2):545–53. DOI: 10.1148/radiol.2362040739Dinis Fernandes C., van Houdt P.J., Heijmink S.W.T.P.J. et al. Quantitative 3T multiparametric MRI of benign and malignant prostatic tissue in patients with and without local recurrent prostate cancer after external-beam radiation therapy. J Magn Reson Imaging 2019;50(1):269–78. DOI: 10.1002/jmri.26581Vargas H.A., Wassberg C., Akin O., Hricak H. MR imaging of treated prostate cancer. Radiology 2012;262(1):26–42. DOI: 10.1148/radiol.11101996Scialpi M., Martorana E., Scialpi P. et al. MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy. Turkish J Urol 2021;47(6):448–51. DOI: 10.5152/tud.2021.21274Franiel T., Lüdemann L., Taupitz M. MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: the feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequen. Radiother Oncol 2009;93(2):241–5. DOI: 10.1016/j.radonc.2009.08.016Schiavina R., Ceci F., Borghesi M. et al. The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques? Curr Radiopharm 2013;6(2):92–5. DOI:10.2174/1874471011306020005Sanguineti G., Bertini L., Faiella A. et al. Response on DCE-MRI predicts outcome of salvage radiotherapy for local recurrence after radical prostatectomy. Tumori 2021;107(1):55–63. DOI: 10.1177/0300891620908950Valle L.F., Greer M.D., Shih J.H. et al. Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy. Diagn Interv Radiol 2018;24(1):46–53. DOI: 10.5152/dir.2018.17285Tamada T., Sone T., Jo Y. et al. Locally recurrent prostate cancer after high-dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging in localizing tumors. AJR Am J Roentgenol 2011;197(2):408–14. DOI: 10.2214/AJR.10.5772Alonzo F., Melodelim C., Bratan F. et al. Detection of locally radiorecurrent prostate cancer at multiparametric MRI: Can dynamic contrast-enhanced imaging be omitted? Diagn Interv Imaging 2016;97(4):433–41. DOI: 10.1016/j.diii.2016.01.008Cirillo S., Petracchini M., Scotti L. et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 2009;19(3):761–9. DOI: 10.1007/s00330-008-1174-8Sandgren K., Westerlinck P., Jonsson J.H. et al. Imaging for the Detection of Locoregional Recurrences in Biochemical Progression After Radical Prostatectomy-A Systematic Review. Eur Urol Focus 2019;5(4):550–60. DOI: 10.1016/j.euf.2017.11.001Barchetti F., Panebianco V. Multiparametric MRI for Recurrent Prostate Cancer Post Radical Prostatectomy and Postradiation Therapy. Biomed Res Int 2014;2014:316272. DOI: 10.1155/2014/316272Kwon T., Kim J.K., Lee C. et al. Discrimination of local recurrence after radical prostatectomy: value of diffusion-weighted magnetic resonance imaging. Prostate Int 2018;6(1):12–7. DOI: 10.1016/j.prnil.2017.05.002Kitajima K., Hartman R.P., Froemming A.T. et al. Detection of Local Recurrence of Prostate Cancer After Radical Prostatectomy Using Endorectal Coil MRI at 3 T: Addition of DWI and Dynamic Contrast Enhancement to T2-Weighted MRI. AJR Am J Roentgenol 2015;205(4):807–16. DOI: 10.2214/AJR.14.14275Panebianco V., Barchetti F., Sciarra A. et al. Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur Radiol 2013;23(6):1745–52. DOI: 10.1007/s00330-013-2768-3Casciani E., Polettini E., Carmenini E. et al. Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol 2008;190(5):1187–92. DOI: 10.2214/AJR.07.3032Litwin M.S., Tan H.J. The Diagnosis and treatment of prostate cancer: a review. JAMA 2017;317(24):2532–42. DOI: 10.1001/jama.2017.7248Nanni C., Schiavina R., Brunocilla E. et al. 18F-Fluciclovine PET/CT for the detection of prostate cancer relapse: a comparison to 11C-choline PET/CT. Clin Nucl Med 2015;40(8):386–91. DOI: 10.1097/RLU.0000000000000849Calais J., Fendler W.P., Herrmann K. et al. Comparison of 68GaPSMA-11 and 18F-fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence. J Nucl Med 2018;59(5):789–94. DOI: 10.2967/jnumed.117.203257Evangelista L., Briganti A., Fanti S. et al. New clinical indications for (18)F/(11)C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Urol 2016;70(1):161–75. DOI: 10.1016/j.eururo.2016.01.029Calais J., Ceci F., Eiber M. et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, singlearm, comparative imaging trial. Lancet Oncol 2019;20(9):1286–94. DOI: 10.1016/S1470-2045(19)30415-2Afshar-Oromieh A., Vollnberg B., Alberts I. et al. Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis. Eur J Nucl Med Mol Imaging 2019;46(11):2289–97. DOI: 10.1007/s00259-019-04438-wLindenberg L., Mena E., Turkbey B. et al. Evaluating biochemically recurrent prostate cancer: histologic validation of 18F-DCFPyL PET/CT with comparison to multiparametric MRI. Radiology 2020;296(3):564–72. DOI: 10.1148/radiol.2020192018Van den Broeck T., van den Bergh R.C.N., Briers E. et al. Biochemical recurrence in prostate cancer: the European Association of Urology Prostate Cancer Guidelines Panel Recommendations. Eur Urol Focus 2020;6(2):231–4. DOI: 10.1016/j.euf.2019.06.004Pecoraro M., Turkbey B., Purysko A.S. et al. Diagnostic accuracy and observer agreement of the MRI prostate imaging for recurrence reporting assessment score. Radiology 2022 304(2):342–50. DOI: 10.1148/radiol.212252Bergaglio C., Giasotto V., Marcenaro M. et al. The Role of mpMRI in the assessment of prostate cancer recurrence using the PI-RR system: diagnostic accuracy and interobserver agreement in readers with different expertise. Diagnostics (Basel) 2023;13(3):387. DOI: 10.3390/diagnostics13030387